PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

AstraZeneca, Chugai reach patent dispute settlement

AstraZeneca’s rare disease group, Alexion, and Roche’s Chugai Pharmaceutical unit are putting down their weapons.

The two have reached a settlement agreement related to the intellectual rights of Ultomiris (ravulizumab). Both companies will withdraw the lawsuits filed in both the U.S. and Japan, and as a part of their deal, AstraZeneca will pay Chugai $775M in the second quarter, with no other payments or royalties necessary beyond that.

Alexion and Chugai had been in patent war since 2016 when Alexion challenged Chugai’s patents in Europe and Japan. Later in 2018, Chugai filed a lawsuit against Alexion in both Japan and the U.S. AstraZeneca inherited the disagreements when it purchased Alexion last year. The buyout was AstraZeneca’s largest deal to date, coming in at $39B.

Ultomiris works by inhibiting a protein found that triggers an immune reaction called a complement cascade. When this cascade is overly activated, the body’s sensitivity to threat becomes compromised and the immune system begins attacking healthy cells.

The drug is currently approved in the U.S. to treat two rare conditions, paroxysmal nocturnal hemoglobinuria (PNH), and hemolytic uremic syndrome (aHUS), which causes anemia and blood clots.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026